Linked Life Data

12671339

Source:http://linkedlifedata.com/resource/pubmed/id/12671339

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-4-2
pubmed:abstractText
Despite improvement in survival with angiotensin-converting enzyme inhibitors and beta blockers, clinical events for patients with heart failure remain elevated. New therapies for heart failure are needed to improve functional capacity, quality of life, and prognosis. Growth hormone exerts direct and indirect effects on cardiac structure and function. Experimental models of heart failure and small studies have demonstrated significant improvements in cardiac function, hemodynamic parameters, functional capacity, and quality of life. Despite the lack of benefit demonstrated in small, short-term, randomized clinical trials, further studies are needed to assess the potential role of this adjuvant therapy in heart failure patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1527-5299
pubmed:author
pubmed:copyrightInfo
Copyright 2003 CHF, Inc.
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
84-90
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Growth hormone therapy in heart failure: where are we now?
pubmed:affiliation
Hamilton Health Sciences (HHS), HHS-General Division, Hamilton, Ontario, L8L 2X2 Canada.
pubmed:publicationType
Journal Article, Review